penn medicine
penn surgery
penn surgery home penn surgery clinical penn surgery education penn surgery research penn surgery administration

S. Bruce Malkowicz, M.D.
Urology

 
  • Profile Home
  • Appointments
  • Education
  • Memberships
  • Research
  • Publications

Administrative/Clinical Offices:
Perelman Center for Advanced Medicine
West Pavilion, 3rd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
Administrative Assistant: Terri Walker
Administrative Telephone: 215-662-7330
Administrative Fax: 215-662-3955

Contact Information (internal use only)

bruce.malkowicz@uphs.upenn.edu

 

 

 
Faculty Appointments
1982 - 1987 Assistant Instructor in Surgery
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
1987 - 1988 Resident Supervisor in Urology
University of Southern California School of Medicine
Los Angeles, California
 
1988 - 1990 Postdoctoral Researcher in Urology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
1988 - 1990 Associate Scientist
Wistar Institute of Anatomy and Biology
University of Pennsylvania
Philadelphia, Pennsylvania
 
1990 - 1993 Assistant Professor of Urology in Surgery
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
1993 - 1995 Assistant Professor of Urology in Surgery at HUP
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
 
1995 - 2003 Associate Professor of Urology in Surgery at HUP
University of Pennsylvania School of Medicine Philadelphia, Pennsylvania
 
2003 - present Professor of Urology in Surgery at HUP
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
 
2007 - present Thomas D. Stichter Memorial Professor of Urologic Research
University of Pennsylvania
 
Hospital and Administrative Appointments
1990 - present Attending Physician
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
 
1990 - present Co-Director, Urologic Oncology Program
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
 
1990 - present Director of Urologic Oncology
Philadelphia Veterans Administration Medical Center
Philadelphia, Pennsylvania
 
2001 - present Chief of Urology
Philadelphia Veterans Administration Medical Center
Philadelphia, Pennsylvania
 
Education/Training
1973 - 1977 B.A. University of Vermont
 
1977 - 1981 M.D. University of Pennsylvania
 
Post-graduate Training and Fellowship Appointments
1981 - 1982 Intern in Surgery
Hospital of the University of Pennsylvania
 
1982 - 1983 Resident in Surgery
Hospital of the University of Pennsylvania
 
1983 - 1987 Resident in Urology
Hospital of the University of Pennsylvania
 
1987 - 1988 Fellow in Urologic Oncology, Kenneth Norris Jr.
Cancer Hospital and Research Center
University of Southern California Medical Center
Los Angeles, California
 
1988 - 1990 Fellow in Urologic Oncology
Hospital of the University of Pennsylvania
 
Memberships/Societies
 
National
  • National: American Society of Clinical Oncology
  • American Urological Association
  • Association for Academic Surgery
  • Society of University Urologists
  • Urodynamics Society
  • Society of Minimally Invasive Therapy
  • Sigma XI Research Society
  • American Association for the Advancement of Science
  • American Medical Association
  • American College of Surgeons
  • Society of Urologic Oncology
  • Urologic Research Society
  • Society of Basic Urologic Research
  • American College of Surgeons, Fellow
  • National Kidney Foundation
  • American Association of Clinical Urologists
  • Society of Surgical Oncology
  • Society of Pelvic Surgeons
  • Secretary-Treasurer, Society of Pelvic Surgeons
  • American Association of Genitourinary Surgeons
  • President, Society of Pelvic Surgeons
Local
  • The Urological Association of Pennsylvania
  • Pennsylvania Medical Society
  • Philadelphia County Medical Society
  • The Philadelphia Urologic Society
  • The John Morgan Society
  • Board of Directors, American Cancer Society
    • Philadelphia Branch - 1994 - 2004
  • Prostate Cancer Subcommittee - Chairman, American Cancer Society
  • Division Committee, Detection - Prostate Cancer
  • American Cancer Society, Southeast Pennsylvania Division
  • President American Cancer Society, Southeast Pennsylvania Division 2000-2002
  • President – Philadelphia Urological Society 2002-2003
Regional Committees
  • Executive Committee, Philadelphia Urologic Society - 1994
  • The College of Physicians of Philadelphia
  • Fellow, Institute on Aging, University of Pennsylvania - 1995
  • Secretary-Treasurer, The Philadelphia Urological Society - 1998 to 2001
  • President, Philadelphia Urological Society 2002-03
 
Research
 
Principal Investigator of Grants
1988 - 1990 American Foundation of Urologic Disease Scholar
Phenotype of Invasive Transitional Cell Carcinoma
 
1990 University of Pennsylvania Cancer Center Grant
Growth Factor Control of Bladder Cancer
 
1990 McCabe Fund. Growth Factor Control of Bladder Cancer
 
1991 McCabe Fund. Integrin Expression in Prostate Cancer
 
1992 McCabe Fund. Combined Monoclonal Antibody Therapy
in Prostate Cancer
 
1992 - 1995 Award No. 92-51 - American Cancer Society
Clinical Oncology Career Development Award. Combined
Monoclonal Antibody Therapy for Advanced Transitional
Cell Carcinoma of the Bladder
 
1993 The University Research Foundation.
Combined Monoclonal Antibody Therapy for Advanced
Transitional Cell Carcinoma of the Bladder
 
1993 (Site Principle Investigator) Prostate Cancer Prevention Trial (PCPT) NIH, SWOG
 
1994 - 1997 (Principle Investigator) V.A. Merit Review Grant.
Metastatic Phenotype of Bladder Cancer
 
1995 (Co-Investigator) CaP Cure. Receptor mediated strategies in prostate cancer
 
1996 (Co-Investigator)A Randomized Double Blind Comparative Trial of Bicalutamide (Casodex) versus Placebo in Patients with Early Prostate Cancer (Zeneca)
 
1996 (Co-investigator) Role of BIN1 in Apoptosis and Prostate Cancer, CaP CURE
 
1997 (Co-Investigator) Role of BIN1 in Apoptosis and Prostate Cancer, CaP CURE
 
1997 (Co-investigator) Role of Bowman-Birk Inhibitor Concentrate
(BBIC) on Bladder Outlet Obstruction (BBI Pharmaceutical)
 
1998 (Principle Investigator) VA Merit Review Grant.
Metastatic Phenotype of Bladder Cancer
 
1999 (Principle Investigator) MatriTech – Role of NMP22 in Hematuria Evaluations
 
1999 (Principle Investigator) BTA TRAK in monitoring patients with established TCC [Bion Science]
 
2000 (NIH- SWOG) Site- Principle Investigator - Selenium and Vitamin E Trial (SELECT)
 
2000 DOD (Co-Investigator) Photodynamic Therapy of Prostate Cancer after radiation failure.
 
2001 [141,000] (Principle Investigator) VA Merit Review, Metastatic Phenotype of Bladder CA
 
2002 Co-PI, The Effect of Taxotere on the Growth of Human Bladder Tumors Treated with Cell Cycle Regulatory Gene Containing Adenovirus
 
2003 PI [Centocor], A phase I study of a polynucleotide anti-tumor immunization to human prostate-specific antigen (PSA) in patients with hormone-refractory cancer (HRPC)
 
2003 Co-Investigator NIH U01-CA86739 The Mid-Atlantic Prostate Cancer Bank
 
2004 PI [GTX] The Effect of Toremifine Citrate in the Prevention of Bone Mineral Density Loss in Patients Receiving Androgen Blockade Therapy
 
Publications
 
Original Papers Peer Reviewed
  1. Levin RM, Malkowicz SB, Jacobowitz D, and Wein AJ: The ontogeny of the autonomic innervation and contraction of the rabbit urinary bladder. J. Pharmacol. Exper. Ther., 219: 250-257, 1981.
  2. Levin RM, Malkowicz SB, and Wein AJ: Laboratory models for neuropharma¬cological studies. World J. Urol., 2: 222-233, 1984.
  3. Malkowicz SB, Atta MA, Elbadawi A, Wein AJ, and Levin RM: The effect of parasympathetic decentralization on the feline urinary bladder. J. Urol., 133: 521-523, 1985.
  4. Malkowicz, SB, A, Wein AJ, and Levin RM: Calcium antagonist affinity for adrenergic anticholinergic receptors in rabbit urinary bladder. Neurology and Urodynamics., 4: 143-148, 1985.
  5. Malkowicz SB, Wein AJ, Brendler K, and Levin RM: Effect of diltiazem on in-vitro rabbit bladder function. Pharmacology, 31, 24-33, 1985.
  6. Levin RM, Malkowicz SB, Wein AJ, Atta MA, and Elbadawi A: Recovery from short-term obstruction of the rabbit urinary bladder. J. Urol., 134: 388-390, 1985.
  7. Malkowicz SB, Wein AJ, Ruggieri MR, Van Arsdalen KN, and Levin RM: The biochemical functional alterations of the partially obstructed rabbit urinary bladder. J.Urol., 136: 1324-1329, 1986.
  8. Levin RM, Ruggieri MR, Hypolite JA, Malkowicz SB, and Wein AJ: Surface spectro-fluorometry of the rabbit urinary bladder. Neurourology and Urodynamics 6: 109-118, 1987.
  9. Malkowicz SB, Wein AJ, Ruggieri MR, and Levin RM: Comparison of calcium antagonist properties of antispasmodic agents. J. Urol. 138: 667-670, 1987.
  10. Elbadawi A, Meyer S, Malkowicz SB, Wein AJ, Levin RM, and Atta MA: Effects of short-term partial bladder outlet obstruction on the rabbit detrusor: An ultrastructural study. Neurourology and Urodynamics 8: 89-116, 1989.
  11. Malkowicz SB, Avon M, Thangathurai D, Viijoen JF, and Skinner DG: Intravenous papaverine in constructing a continent urinary reservoir. Urology, 33:431-432, 1989.
  12. Malkowicz SB, and Skinner DG: The development of upper tract carcinoma after cystectomy for bladder cancer. Urology, 36, 20-22, 1990.
  13. Malkowicz SB, Nichols PW, Lieskovsky G, Boyd S, Huffman J, and Skinner DJ: The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, Pl, PIS, P2). J. Urology, 144: 641-645, 1990.
  14. Cendron M, Deserable D, Malkowicz SB and Wein AJ: The Urology Crash Box, J. Urology, 146: 389-391, 1991.
  15. Herlyn M and Malkowicz SB: Biology of Disease: Regulatory pathways in tumor growth and invasion. Laboratory Investigation. 65: 262-271, 1991.
  16. Linnenbach AJ, Pressler LB, Seng BA, Kimmel Barry S, Tomaszewski John E, and Malkowicz SB: Characterization of chromosome 9 deletions in transitional cell carcinoma by microsatellite assay. Human Molecular Genetics, 2: 1407-1411, 1993.
  17. Kariko K, Malkowicz SB, Li WJ, Kuo A, and Barnathan ES: Invasive neoplastic uroepithelial cells express high levels of urokinase receptor and plasminogen receptor, alpha-enolase. International Journal of Oncology. 3: 1089-1095, 1993.
  18. D'Amico A, Altschuler M., Whittington R., Kao G, and Malkowicz S B: The use of clinical parameters in an interactive statistical package to predict pathologic features associated with local failure after radical prostatectomy. Clinical Performance and Quality Health Care. 219-222, 1993.
  19. Linnenbach AJ, Robbins SL, Seng BA, Tomaszewski JE, Pressler LB, and Malkowicz SB: Urothelial carcinogenesis. Nature: 367, 419-420, 1994.
  20. D'Amico AV, Whittington R, Malkowicz SB, Schnall M, Tomaszewski J, Schultz D, Kao G, Van Arsdalen K, and Wein AJ: A multivariable analysis of clinical factors predicting for pathologic features associated with local failure after radical prostatectomy for prostate cancer: International Journal Radiation Oncology Biol Phys. 30: 293-303, 1994.
  21. Kao GD, Malkowicz SB, Whittington R, D'Amico A. and Wein AJ: Locally advanced renal cell carcinoma: low complication rate and efficacy of postnephrectomy radiation therapy planned with CT. Radiology. 193: 725-730, 1994.
  22. Malkowicz SB, Thomas J, and Levin RM: The effect of cholinergic stimulation on cultured smooth muscle cells in bladder muscle and matrix. Editor, S. Zderic, Advances in experimental medicine and biology 385: 257-260, 1995.
  23. D'Amico AV, Whittington R, Schnall M, Malkowicz SB, Tomaszewski JE, Schultz D, Wein AJ: The impact of inclusion of endorectal coil MRI in a multivariate analysis to predict for extraprostatic disease. Cancer 75: 2368-2372, 1995.
  24. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, and Wein AJ: A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. The Journal of Urology. 154, 131-138, 1995.
  25. Gilbert JB, Malkowicz SB, and Wein AJ: Cell saver and radical retropubic prostatectomy: analysis of cost effectiveness. Urology 46, 4: 542-544, 1995.
  26. D'Amico AV, Whittington R, Malkowicz SB, and Schultz D: A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer. Int J Radiation Oncology Biol. Phys. 32, 2: 473-477, 1995.
  27. Whitttington R, Malkowicz SB, Barnes MD, Broderick GA, Van Arsdalen K, Dougherty MJ, Wein AJ: Combined hormonal and radiation therapy for lymph node positive prostate cancer. Urology 46, 2: 213-219, 1995.
  28. Kimmel BS, Miniou P, Robbins SL, Malkowicz, SB, Linnenbach AJ: Three new dinucleotide repeat polymorphisms on human chromosome 9: D9S970, D9S971, and D9S972. Human Genetics 96: 237-239, 1995.
  29. Sion-Vardy N, Vardy D, Ulrich R., Kari C, Levin RM and Malkowicz SB: Antiproliferative effects of tyrosine kinase inhibitors tyrphostins on human bladder and renal carcinoma cells. Journal of Surgical Research. 59: 675-680, 1995.
  30. Langer JE, Rovner ES, Coleman BG, Yin D, Arger PH, Malkowicz SB, Nisenbaum HL, Rowling SE, Tomaszewski JE, Wein AJ, and Jacobs JE: Strategy for rebiopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. Journal of Urology: 155, 228-231, 1996.
  31. D’Amico AV, Whittington R, Malkowicz SB, Loughlin K, Schultz D, Schnall M, Tempany CM, Tomaszewski JE, Renshaw A, and Wein AJ: An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology 47: 538-547, 1996.
  32. Van Arsdalen K, Broderick GA, Malkowicz SB and Wein AJ: Laparoscopic lymphadenectomy based on magnetic resonance imaging: is a unilateral dissection adequate for staging prostate cancer? Techniques in Urology 2: 93-98, 1996.
  33. D’Amico AV, Whittington R, Malkowicz SB, Delray S, Schnall M, Tomaszewski J, and Wein AJ: Critical analysis of the ability of the endorectal coil MRI imaging scan to predict pathologic stage, margin status, and post-operative prostate-specific antigen failure in patients with clinically organ confined prostate cancer. Journal of Clinical Oncology 14: 1770-1777, 1996.
  34. Malkowicz SB, Tomaszewski JE, Linnenbach A, Cangiano TA, Maruta Y, and McGarvey TW: Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinoma. Oncogene 13: 1831-1837, 1996.
  35. McGarvey TW and Malkowicz SB: The role of cell cycle in genitourinary carcinoma. World Journal of Urology 14: 310-317, 1996.
  36. Turek PJ, Malkowicz SB, Tomaszewski JE, Wein AJ and Peehl D: The role of the sertoli cell in active immunosupression in the human testis. British Journal of Urology 77: 891-895, 1996.
  37. Chaikin DC, Broderick GA, Malloy TR, Malkowicz SB, Whittington R and Wein AJ: Erectile dysfunction following minimally invasive treatments for prostate cancer. Urology 48: 1996.
  38. D’Amico A, Whittington R, and Malkowicz SB: Role of percent positive biopsies and endorectal coil MRI in predicting prognosis in intermediate-risk prostate cancer patients. The Cancer Journal from Scientific American: 2: 343-350, 1996.
  39. Langlotz CP, Schnall C, Malkowicz SB, and Schwartz JS: The cost effectiveness of endorectal MRI for staging of prostate cancer. Academic Radiology 3: S4-7, 1996.
  40. Loh E, Fergus JC, Carrie Hendricksen BS, Farid L, Kelly PF, Acker MA, Tomaszewski JE, Malkowicz SB, and Weber BL: Brief report: development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation. JAMA 277: 133-137, 1997.
  41. D’Amico A, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomasewski JE and Wein AJ: Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 49: 23-30, 1997.
  42. Vaughn DJ, Malkowicz SB, Zoltick B, Ramchandani P, Tonkonow B, Armstead B and Wein AJ: Phase I Trial of Paclitaxel/Carboplatin in Advanced Carcinoma of the Urothelium. Seminars in Oncology 24: S2-47 - S2-50, 1997.
  43. D’Amico A, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE and Wein AJ: Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial. J of Clin Onco 15: 1465-1469, 1997.
  44. Ebling DW, Ruffer J, Whittington R, Van Arsdalen K, Broderick GA, Malkowicz SB, and Wein AJ: Development of prostate cancer after pituitary dysfunction: a report of 8 patients. Urology 49: 564-568, 1997.
  45. D’Amico A, Whittington R, Schultz D, Malkowicz SB, Tomaszewski J, and Wein AJ: Outcome based staging for clinically localized adenocarcinoma of the prostate. J of Urology 158: 1422-1426, 1997.
  46. Rovner EJ, Schanne FJ, Malkowicz SB and Wein AJ: Transurethral biopsy of the prostate for persistently elevated or rising PSA following multiply negative transrectal biopsies. The Journal of Urology 158: 138-142, 1997.
  47. Malkowicz SB: Superficial bladder cancer: The role of molecular markers in the treatment of high risk superficial disease. Seminars in Urologic Oncology 15: 169-178, 1997.
  48. D’Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein AJ, Coleman CN. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with pretreatment prostate specific antigen of > 4-20 ng/ml. International Journal of Radiation Oncology, Biology, Physics. 37(5): 1053-8, 1997.
  49. Sanchez-Ortiz Ricardo F, Broderick GA, Chaiken DC, Malkowicz SB, Van Arsdalen K, Blander DS, and Wein AJ: Collagen injection therapy for post-radical retropubic prostatectomy incontinence: role of valsalva leak point pressure. J of Urol 158: 2132-2136, 1997.
  50. Werner Wasik M, Whittington R, Malkowicz SB, Corn BW, Arger P, Reisinger S, Langlotz C, Alexander A, D’Amico AV, Hyslop T, Gomella L, Brownstein K, and Wein AJ: Prostate imaging may not be necessary in non-palpable carcinoma of the prostate. Urol 50: 385-389, 1997.
  51. Whittington R, Malkowicz SB, Machtay M, Van Arsdalen K, Barnes MM, Broderick GA, and Wein AJ: The use of combined radiation therapy and hormonal therapy in the management of lymph node positive prostate cancer. Int J Rad Bio Phys 39: 673-680, 1997.
  52. D’Amico AV, Schnall M, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, and Wein AJ: Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 51: 451-454, 1998.
  53. McGarvey TW, Kariko K, Barnathan ES, Thomas J and Malkowicz SB: The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma. Int J of Oncology 12: 175-180, 1998.
  54. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw A, Loughlin KR, Richie JP, Wein AJ: Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external beam radiation therapy. J of Clin Onc 16: 3094-3100, 1998.
  55. Gottschalk A, Smith DE, Jobes DR, Kennedy SK, Lally SE, Noble VE, Grugan KF, Seifert HA, Cheung A, Malkowicz SB, Gutsche BB, and Wein AJ: Preemptive epidural analgesia and recovery from radical prostatectomy. JAMA 279: 1076-1082, 1998.
  56. D’Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein AJ, Tomaszewski JE, and Coleman CN: Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pre-treatment PSA levels of 4-20 nanograms per milliter. Cancer: 82: 334-41, 1998.
  57. Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Armstead B, Fox K, and Wein AJ: Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncology 16: 255-260, 1998.
  58. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, and Wein AJ: A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urol 52: 631-636, 1998.
  59. Sanchez-Ortiz RF, Fraker DL, and Malkowicz SB: Renal cell carcinoma with mesenteric thrombosis and anticardiolipin antibodies: echoes of trousseau’s syndrome? The Journal of Urology 159: 2078, 1998.
  60. D’Amico Av, Whittington R. Malkowicz SB, Fondurulai J, Chen MH, Tomaszewski JE, Wein AJ: The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 160: 2096-2101, 1998.
  61. D’Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein AJ, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP: Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 82: 1887-96, 1998.
  62. Manzone TA, Malkowicz SB, Tomaszewski JE, Schnall MD, Langlotz CP: The use of endorectal MR imaging to predict prostate carcinoma recurrence following radical prostatectomy. Radiology: 209 (2) 537-42, 1998.
  63. D’Amico AV, Whittington R, Malkowicz SB, Blank K, Broderick GA, Schultz D, Tomaszewski JE, Kaplan I, Beard C, and Wein AJ: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 16: 1008-1010, 1998.
  64. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, and Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Nat’l Ca Institue 90: 1225-1229,1998
  65. McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ and Malkowicz SB: PTCH Gene Mutations in Invasive Transitional Cell Carcinoma of the Bladder. Oncogene 17: 1167-1172, 1998.
  66. Bernstein MR, Wein AJ, Siegelman ES, Tomaszewski JE, and Malkowicz SB: Lack of correlation of clinical and pathologic staging of capsular involvement in prostate cancer using endorectal coil magnetic resonance imaging. Journal of Pelvic Surgery 5: 203-207, 1999.
  67. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Ming-Hui C, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw A, Wein AJ, and Coleman CN: Pre-treatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer. J Clin Onc 17: 168-172, 1999.
  68. Parsons JK, Malkowicz SB, and Torosian M: A simplified procedure for creating a urinary conduit in patients with a colostomy. Oncology Reports 6: 451-453, 1999.
  69. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ and Malkowicz SB: Glutathione S-transferase - mu (GSTM1) and theta (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 8: 283-287, 1999
  70. D’Amico AV, Whittington R, Makowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A: Optimizing Patient Selection For Dose Escalation Techniques Using the Prostate Specific Antigen Level, Biopsy Gleason Score, and Clinical T-Stage. Inter. J. Of Rad. Onc., Biol. 45:1227-33, 1999
  71. Whittington R, Broderick GA, Arger P, Malkowicz SB, Epperson RD, Arjomandy B, and Kassaee A: The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J of Rad Onc, Bio, Phys 44(5): 1107-10, 1999
  72. Blank KR, Whittington R, Arjomandy B, Wein AJ, Broderick G, Staley J, and Malkowicz SB: Neoadjuvant androgen deprivation prior to transperineal prostate brachtherapy: smaller volumes, less morbidity. Ca Journ of Scien. Amer. 5:370-373, 1999.
  73. Blander DS, Broderick GA, Malkowicz SB, VanArsdalen K, and Wein AJ: Retrospective Review of Flow Patterns Following Radical Prostatectomy. Int. J. of Impot. Res 11:309-13, 1999
  74. McGarvey TW, Tait E, Tomaszewski JE, and Malkowicz SB: Expression of transforming growth factor-beta receptors and related cell cycle components in transitional cell carcinoma of the bladder. Molecular Urol, 3: 371-379, 1999.
  75. D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, Tomaszewski JE, Wein A: Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 55(4):572-577, 2000
  76. McGarvey TW and Malkowicz SB: Steady state expression of cell cycle regulatory genes in prostate carcinoma cell lines. Urologic Oncology 5:71-77, 2000
  77. D’Amico AV, Whittington R, Malkowicz B, Schnall M, Schultz D, Cote K, Tomaszewski JE, Wein A: Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J of Urol 164:759-763, 2000
  78. Ge K, Minhas F, DuHadaway J, Mao NC, Wilson D, Nelson P, Malkowicz SB, Tomaszewski J and Prendergast GC: Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Internat J Ca 86:155-161, 2000.
  79. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Tomaszewski J,Van Arsdalen K, Wein AJ and Rebbeck: Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 60:1626-1630, 2000
  80. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Ming-Hui C, Tomaszewski JE, Renshaw AA, Wein A, Richie JP: Clinical Utility of the Percentage of Positive Prostate Biopsies in Defining Biochemical Outcome After Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. J. Clin. Oncol. 18:1164-1172, 2000
  81. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A: Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or =7. Cancer 88:2110-2115, 2000
  82. Bernstein MR, Cangiano TA, D’Amico A, Chittams J, Hardy C, Whittington RD, Tomaszewski JE, Schnall MD, Wein AJ, and Malkowicz SB: Endorectal coil magnetic resonance imaging and clinco-pathologic findings in T1c adenocarcinoma of the prostate. Urologic Oncology 5:104-111, 2000
  83. D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen MH, Hurwitz M, Kantoff PW, Tomaszewski JE, Renshaw AA, Wein AJ, Richie JP: Utilizing predications of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J of Clin Onc 18:3240-3246, 2000.
  84. Rebbeck TR, Walker AH, Zeilger-Johnson CM, Weisburg S, Martin A-M, Nathanson KL, Wein AJ, Malkowicz SB: Association of HPC2/ELAc2 Genotypes and Prostate Cancer, Am J Hum Genet, 61:1014-1019, 2000
  85. D’Amico aV, Whittington R, Malkowicz SB, Schultz, Silver B, Henry L, Hurwitz, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer and Prostatitic Diseases 3:259-264, 2000
  86. Malkowicz S.B., Intravesical Therapy for Superficial Bladder Cancer. Seminars in Urol Onc. 18:280-288, 2000
  87. Kelada SN, Kardia SLR, Walker AH, Wein AJ, Malkowicz SB, Rebbeck TR. The Glutathione S-Transferase-u and –0 Genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Can Epidemiology, Biomarkers & Prevention 9:1329-1334, 2000
  88. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein AJ, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Molecular Urol 4(3):171-5 discussion 177, 2000
  89. Sanchez-Ortiz RF, Rovner ES, Broderick GA, Whittington R, Wein AJ, Malkowicz SB: Erectile Function and Health Related Quality of Life After Interstitial Radiation Therapy For Prostate Cancer, Int. J. Impot. Res. 12:518-524, 2000
  90. Cheung R, Altschuler MD, D’Amico AV, Malkowicz SB, Wein AJ, Whittington R: ROC-optimized risk stratification improves predictive accuracy on the outcomes of individual prostate cancer patients, Urology 57:286-290, 2001
  91. McGarvey TW, Nguyen T, Tomaszewski JE, Monson FC, Malkowicz SB. Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder. Oncogene 20:1042-1052, 2001
  92. Vaughn DJ and Malkowicz SB: Recent advances in bladder cancer chemotherapy. Cancer Investigation 19:1-9, 2001
  93. Nathanson KL, Omaruddin R, Malkowicz SB, Rebbeck TR: Intronic variant in PTEN is not associated with prostate cancer risk. Cancer Epidemiology Biomarkers and Prevention 10:277-278, 2001
  94. Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SHF, Wein AJ, Kennedy AR. Effects of Bowman-Birk Inhibitor Concentrate (BBIC) in Patients with Benign Prostatic Hyperplasia. The Prostate 48:16-28, 2001
  95. Stein S, Zoltick B, Peacock T, Holroyde C.Haller, D, Armstead B, Malkowicz SB, Vaughn DJ. Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial [Clinical Trial, Clinical Trial, Phase I. Journal Article] Amer Jour Clin Onc 24(3):283-5, 2001
  96. McGarvey TW, Meng RD, Johnson O, El-Deiry W, Malkowicz SB. Growth Inhibitory Effect of p21 and p53 Containing Adenoviruses on Transitional Cell Carcinoma Cell Lines in vitro and in vivo. Urologic Oncology 6:155-162, 2001
  97. Malkowicz SB: The Role of DES in the Treatment of Prostate Cancer, Urology 58:108-113, 2001
  98. Cheung R, Altschuler MD, D’Amico AV, Malkowicz SB, Wein AJ, Whittington R. Using the ROC curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure. Urology 58: 400-405, 2001
  99. D’Amico AV, Whittington R, Malkowicz SB, Renshaw AA, Tomaszewski JE, Bentley C, Schultz D, Rocha S, Wein A, and Richie J. Estimating the impact on prostate cancer mortality of incorporating prostate-specific antigen testing into screening. Urology 58: 406-410, 2001
  100. D’Amico AV,Whittington R, Malkowicz SB, Weinstein M, Tomazewski JE, Schultz D, Rhude M, Rocha S, Wein AJ, Richie JP. Predicting Prostate Specific Antigen outcome preoperatively in the Prostate Specific Antigen Era. J. Urology 166:2185-2188, 2001
  101. Arger PH, Malkowicz SB, VanArsdalen KN, Sehgal CM, Holzer A, and Barret R. J. Impact on Prostate Cancer Detection Using Added Biopsy Areas:Preliminary Analysis. J of Ultrasound Med. 21:135-139, 2002
  102. D’Amico AV, Chen MH, Malkowicz, SB, Whittington R, Renshaw AA, Tomaszewski JE, Samofalov, Y, Wein AJ, Richie JP. Lower Prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate cancer and a prostate specific antigen level of 4 ng./ml or less. J. Urology 167:2025-2031, 2002
  103. Cross CK, Shultz D, Malkowicz SB, Huang WC, Whittington, Tomaszewski JE, Renshaw AA, Richie JP, and D’Amico AV. Impact of race on prostate specific antigen outcome after radical prostatectomy for clinically localized adenocarcinoma of the prostate. J. Clin. Oncology 20:2863-2868, 2002
  104. Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A Richies JP and D’Amico AV. Using PSA biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int. J. of Rad. Onc.,Biol, Physics. 53:898-903,2002
  105. D’Amico AV, Whittington R. Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE Renshaw AA, Wein A Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95:281-6, 2002
  106. Robnett TJ, Whittington R, Malkowicz SB, Bereton HD, VanArsdalen K, Drach G, Wein AJ. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int. J. of Rad. Onc. Biol. Physics. 53:1146-1151, 2002.
  107. Huang WC , Taylor S, Nguyen TB, Puthiyaveettil R Tomaszewski, JE, Libertino J, Malkowicz SB, and McGarvey T. KIAA1096, a gene on chromosome 1q, is amplified and overexpressed in bladder cancer. DNA and Cell Biology 21:707-715, 2002
  108. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Malkowicz SB, Ofori-Adjei D, Gueye SM, and Rebbeck TR. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Human Heredity 54:13-21, 2002
  109. McHale T., Malkowicz SB, Tomaszewski JE, and Genega EM. Potential pitfalls in the frozen section evaluation of parenchymal margins in nephron-sparing surgery. American Journal of Clinical Path. 118:903-10, 2002.
  110. McGarvey TW, Nguyen TB, Tomaszewski JE, and Malkowicz SB. The isolation of an immortalized/tumorigenic cell line from p21WAF1 null mouse bladders. In Vitro Cell Dev. Biol. Anim. 38:394 -400, 2002
  111. Sanchez-Ortiz RF, Huang W, Van Arsdalen KN, Wein AJ, Malkowicz SB. An Interval Longer Than 12 Weeks Between Diagnosis Of Muscle Invasion And Cystectomy Is Associated With Worse Outcome In Bladder Carcinoma. J.Urology 169:110-115, 2003
  112. Malkowicz SB, Liu SP, Broderick GA, Wein AJ, Kennedy AR, and Levin RM. The effect of the Bowman-Birk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity. Urodynamics and Neurourology 22:54-57, 2003
  113. Cheng GC, Chen MH, Whittington R, Malkowicz SB, Schnall MD, Tomaszewski JE, D”Amico AV. Clinical utility of endorectal MRI in determining PSA outcome for patients with biopsy Gleason score 7, PSA < 10, and clinically localized prostate cancer. Int J.Radiat Oncol Biol Phys 55:64-70, 2003
  114. McGarvey TW, Nguyen T, Puthiyaveettil R, Tomaszewski JE, Malkowicz SB. TERE 1, a novel gene affecting growth regulation in prostate carcinoma. Prostate 54:144-55, 2003
  115. Gueye SM, Seigler-Johnson, CM, Friebel T, Spangler E, Jalloh M, McBride S, Malkowicz SB, and Rebbeck TR. Clinical characteristics of prostate cancer in African Americans, Caucasian, and Senegalese Men. Urology 61:987-992, 2003
  116. Seethala RR, Tirkes AT, Weinsten S, Tomaszewski JE, Malkowicz SB, Genega EM. Diffuse fibrous pseudotumor of the Testicular tunics associated with an inflamed hydrocele. Archives of Pathology and Laboratory Medicine.127:742-4, 2003
  117. Chung B, Malkowicz SB, Nguyen TB; Libertino JA and McGarvey TW. The expression of the proto-oncogene Axl in renal cell carcinoma. DNA and Cell Biology 22:533-40, 2003
  118. Flaherty KT, Malkowicz SB, Vaughn DJ. A Phase 1 study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. American J. of Clin. Oncol. 27:136-139, 2004
  119. Rathmell WK, Malkowicz SB, Holroyde C, Luginbuhl W, Vaughn DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am J. Clin Oncol. 27:109-112, 2004
  120. Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski, Puthiyaveettil R, Malkowicz SB and Helfman DM. Alterations in tropmyosin isoform expression in human transitional cell carcinoma [TCC] of the urinary bladder. Int. J. of Ca 110:368-73,2004
  121. ArgerPH, Malkowicz SB, VanArsdalen KN, Sehgal CM, Holzer A, and Shultz SM. Color and power Doppler sonography in the diagnosis of prostate cancer:comparison between vascular density and total vascularity. J. Ultrasound Med. 23:623-630, 2004
  122. Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, and Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med. 164:1227-30, 2004
  123. McAllister M, Bhayani S, Ong A, Jaffe W. Malkowicz SB, VanArsdalen K, Chow GK and Jarrett T. Vena cava transection during retroperitoneoscopic nephrectomy: Report of 2 cases and review of the literature. J. Urol 172:183-185,2004
  124. Shapiro PJ , Coyne JC, , Kruus LK, Palmer SC, Vaughn DJ, Malkowicz SB. Interest in services among prostate cancer patients receiving androgen deprivation therapy. J Psyco-oncology 13:512-525, 2004.
  125. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O’Mera S, Smith R, Parker A, Barthorpe A, Blow M, Bracenbury, L. Butler A, Clarke O. Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K Kosmidou V, Lugg R, Menzies A, Oerry J, Petty R, Raine K, Ratford L, Shepaerd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, BrasseurB, Cooper C, A Flanagan, Greaves M, Knowles M, Leung SY, Louis DN, Looijenga LHJ, Malkowicz B, Pierotti M, The B, Weber BL, Wolfel T, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futeal A, Wooster R, Stratton M. Intragenic mutations of ERBB2(HER-2/neu) in lung cancer. Nature 431:525-526, 2004
  126. Zeigler-Johnson C, Walker, AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplene R, Wein AJ, Malkowicz SB, Rebbeck TR. CYP3A4,CYP3A5. and CYP 3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Research 64:8461-8467, 2004
  127. Spangler E, Zeigerl-Johnson CM, Malkowicz SB, Wein A, and Rebbeck TR. Association of prostate cancer family History with Histopathological and Clinical characteristics of prostate tumors. Int. J. Cancer 113:471-474, 2004
  128. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, Spangler E, Leonard DG, Wein A, Malkowicz SB, Rebbeck TR. Association of susceptibility Alleles in ELAC2/HPC2,RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American Men. Cancer Epidemiol Biomarkers Prev 14:949-57, 2005
  129. Genega EM, Kapali M, Torres-Quinones M, Huang WC, Knauss JS, Wang LP, Raghunath P, Kozlowski C, Malkowicz SB, and Tomaszewski JE. Impact of the 1998 World Health Organization/International Society of Urological Pathology classification system for urothelial neoplasms of the kidney. Modern Pathology 18:11-18, 2005
  130. McGarvey TW, Nguyen T, and Malkowicz SB. The interaction of TERE1 and Apolipoprotein E: a role in bladder cancer growth control? J. of Cellular Biochemistry 95:419-428, 2005
  131. Zhu TC, Glatstein E, Hahn, S Dimofte A, Finlay JC, Stripp D, Busch T, Miles J, Whittington R, Malkowicz SB, Tochner Z. Optical properties of human prostate at 732 nm measured in vivo during motexafin lutetium-mediated photodynamic therapy. (in press) Photochemistry and Photobiology 81:96-105, 2005
  132. Jayadevappa R, Chhatre S, Weiner M, Bloom BS, Malkowicz SB. Direct medical care cost of patients with prostate cancer. Urologic Oncology 23:155-162, 2005
  133. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O’Mera S, Smith R, Parker A, Barthorpe A, Blow M, Bracenbury, L. Butler A, Clarke O. Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K Kosmidou V, Lugg R, Menzies A, Oerry J, Petty R, Raine K, Ratford L, Shepaerd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, BrasseurB, Cooper C, A Flanagan, Greaves M, Knowles M, Leung SY, Louis DN, Looijenga LHJ, Malkowicz B, Pierotti M, The B, Weber BL, Wolfel T, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futeal A, Wooster R, Stratton M Tyrosine Kinase mutations in breast cancer patients. Nature Genetics 37:590-92, 2005
  134. Jayadevappa R,, Bloom BS, Fomberstein K, Wein AJ, Malkowicz SB. Health related quality of life and direct medical care cost of newly diagnosed younger men with prostate cancer. J. Urol. 174:1059-64, 2005
  135. Guzzo TJ, Vira MA, Hwang WT, D’Amico AV, Tomaszewski JE, Whittington R, Wein AJ, VanArsdalen K, and Malkowicz SB. The effect of multiple biopsy cores on predicting final tumor volume in prostate cancer detected by a single microscopic focus of cancer on biopsy. Urology 66:361-365, 2005
  136. Davies H , Hunter C, Smith R, Stephens P, , Bignell G, Edkins S, , Teague J, Stevens C, O’Mera S, , Parker A, Barthorpe A, Blow M, Bracenbury, L. Butler A, Clarke O. Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K Kosmidou V, Lugg R, Menzies A, Oerry J, Petty R, Raine K, Ratford L, Shepaerd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, BrasseurB, Cooper C, A Flanagan, Greaves M, Knowles M, Leung SY, Louis DN, Looijenga LHJ, Malkowicz B, Pierotti M, The B, , Wolfel T, Yuen ST, Harris G, Weber BL , Goldstraw P, Nicholson AG, , Wooster R, Stratton M. Futreal A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Research 65:7591-95, 2005
  137. Vaughn DJ, Rizzo TA, and Malkowicz SB. Chemosensitivity of ovarian-type surface epithelial tumor of the testis. Urology 66:658, 2005
  138. McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, and D’Amico AV. PSA outcome following radical prostatectomy for patients with localize prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urolologic Oncology 23:311-17, 2005
  139. Vira,MA Tomaszewski JE, Hwang WT, D’Amico A V, Whittington R, VanArsdalen K, Wein AJ, and Malkowicz SB. Impact of percent positive biopsy cores on the further stratification of pattern 3 and pattern 4 dominant gleason score 7 tumors in radical prostatectomy patients. Urology 66:1015-1019, 2005
  140. Guzzo TJ, Vira M, Wang Y, Tomaszewski JE, D’amico AV, Wein AJ, and Malkowicz SB. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J. Urol 175:518-522, 2006
  141. Lee, R, Armstrong K, Localio AR, Huang R, Malkowicz SB, and Schwartz JS. A Meta-analysis of the performance characteristics of the free PSA test. Urology 67:762-768, 2006
  142. Clark T, Malkowicz SB, Stavropoulos SWW, Sanchez R, Soulen MC, Itkin M, Patel A, Mondschein JI,Wein AJ. Radiofrequency ablation of small renal cell carcinomas using multitined, expandable electrodes:preliminary experience. J. Vascular Interv. Radiol. 17:513-519, 2006
  143. Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, and Malkowicz SB. Health related quality of life and satisfaction among older men treated with radical prostatectomy or external beam radiation therapy. British J. Urol. Int. 97:955-962,2006
  144. Verigos K, StrippDC, Mic R, Zhu TC, Whittington R, Smith D, Dimofte A, Finlay J, Busch TM, Tochner ZA, Malkowicz S, Glatstein E, Hahn SM. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J. Environ Pathol. Toxicol Oncol. 25:373-388, 2006
  145. Du KL, Mick R, Busch TM, Zhu TM, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM. Preliminary results of intersitital motexafin lutetium-mediated PDT for prostate cancer. Laser Surg Med. 38:427-434, 2006
  146. Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, and D’Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology 68:367-70, 2006
  147. Kutikov A, Fossett LK, Tomazewski JE, Siegelman ES, Banner MP, Ramchandani P, Van Arsdalen KN, Wein, AJ, and Malkowicz SB. Internal Radiological Review reduces but does not eliminate the incidence of benign mass in patients undergoing partial nephrectomy for solid renal tumor. Urology 68: 737-740, 2006
  148. Malkowicz SB and Ramchandani P, Is there a role for preoperative renal core biopsy?: commentary, Nature Clinical Practice Urology, 3:576-577, 2006
  149. Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Cusch TM and Hahn SM. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochemistry and Photobiology 82, 1270-1278, 2006
  150. Yu G, Durduran T, Zhou TC, Finlay JC, Busch TM, Malkowicz SB, Hahn SM, Yodh AG. Real-time in situ monitoring of human prostate photodynamic Therapy with diffuse light. Photochem. Photobiology. 82:1279-1284, 2006
  151. Malkowicz SB, van Poppel H, Micksch G, Pansadaoro V, Thuroff J, Soloway MS, Schang S, Benson M, Fukui I. Muscle Invasive Bladder Cancer. Urology, 69 (Sup):3-16, 2007
  152. Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, and Malkowicz SB. Ethinic variations in return to baseline values of patient reported outcomes in older prostate cancer patients. Cancer 109:2229-38, 2007
  153. Guzzo T, Vira M, Neway W, Hwang WT, Tomaszewski JE, Van Arsdalen K, Wein AJ, Malkowicz SB. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology 69:1147-51, 2007
  154. Halbert CH, Barg FK, Weathers B, Deimoor E, Coyne J, Wileyto EP, Arocho J, Mahler, and Malkowicz SB. Differences in cultural beliefs and values among African American and European American men with prostate cancer. Cancer Control, 14:277-284, 2007
  155. Spangler E, Zeigler- Johnson, CM, Coomes M, Malkowicz SB, Wein, A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American Men. J. Urol 178:1939-1944, 2007
  156. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS. Toremifine increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study. J. Urol. 179:152-155, 2008
  157. Guzzo T, Levin BM, Lee R, Guo M, Chen Z, Whittington RA, Tomaszewski, JE and Malkowicz, SB. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Urology, 71:723-727, 2008
  158. Vira MA, Guzzo T, Heitjan DF, Tomaszewski JE, D’Amico A, Wein AJ, and Malkowicz SB. Is the biopsy Gleason score important in predicting outcomes for patients following radical prostatectomy once the pathologic Gleason score is known? BJU. Int. 101:1232-6, 2008
  159. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS. Toremifine improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: Interim analyisis of a multicenter Phase III study. J. Clinical Oncology 26:1824-1829, 2008
  160. Cetnar JP, Malkowicz SB, Palmer SC, Wein AJ, Vaughn DJ. Pilot trial of adjuvant paclitaxel plus estramustine in resected, High-risk prostate cancer. Urology 71:942-946, 2008
  161. Zeigler-Johnson C, Rennert H, Mittal D, Jalloh M, Sachdeva R, , Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR. Evaluation of prostate cancer characteristics in four populations worldwide. Can. J. Urol. 15:4056-64, 2008
  162. Patel H, Mick R, Finlaly J, Zhu TX, Rickter E, Cengel KA, Malkowicz SB, Hahn SM, BuschTM. Motexam-lutetium-photodymanic therapy of prostate cancer:short-and long-term effects on prostate specific antigen. Clin Cancer Res. 14:48-69-76, 2008
  163. Rebbeck TR. Rennert H. Waller AH, Panossian S, Tran T, Walker K, Spangler E, Patacsil-Coomes M, Sachdeva R, Wein AJ, Malkowicz SB, Zeigler-Johnson C. Joint effects of inflammation and androgen metabolism on prostate cancer severity. Int. J. Cancer 123:1385-9, 2008
  164. Canter D, Guzzo TJ, Chung B, Vira M, Chen Z, Tomaszewski J, Sanchez R, Van Arsdalen K, Wein AJ, and Malkowicz SB. The impact of hydronephrosis on recurrence and disease specific survival in high grade bladder cancer. Urology 72:379-83, 2008.
  165. Guzzo TJ, Canter D, Kutikov A, Magerfleish L, Wein AJ, Malkowicz SB. Clinical and pathologic history of prostate cancer progression in men with a prior history of high grade prostatic intraepithelial neoplasia. Canadian J. Urol. 15:4174-79, 2008
  166. Wang GJ, Carpenter JP, FairmanRM, Jackson BM, Malkowicz B, VanArsdalen KN, Woo EY. Single-center experience of caval thrombectomy in patients with renal cell carcinoma with tumor thrombus extension into the inferior vena cava. Vasc Endovascular Surg. 42:335-40, 2008
  167. Kutikov A, Fossett LK, Van Arsdalen KN, Guzzo TJ, Wein AJ, Malkowicz SB. Enucleation of renal cell carcinoma with ablation of tumor base: is cancer control comparable to partial nephrectomy? BJU Int. 102:688-691, 2008
  168. Canter D, Guzzo T, Resnick M, Magerfleishch L, Sonnad S, Bergey M, Tomaszewski J, Vaughn D, Van Arsdalen K, Malkowicz SB. The presence of lymphovascular invasion in radical cystectomy specimens from patients with urothelial carcinoma portends a poor clinical prognosis. BJU Int. 102:952-957, 2008
  169. Resnick MJ, Canter DJ, Guzzo TJ, Brucker BM, Bergy MR, Sonnad S, Wein AJ, Malkowicz SB. Does race impact postoperative outcomes in low risk prostate cancer patients who undergo radical prostatectomy? Urology 73:620-623, 2009
  170. Halbert CH, Weathers B, Delmoor E, Mahler B, Coyne J, Thompson HS, Have TT, Vaughn D, Malkowicz SB, Lee D. Racial differences in medical mistrust among men diagnosed with prostate cancer. Cancer 115: 2553-2561, 2009
  171. Jayadevappa R, Chhatre S, Wein AJ, Malkowicz SB. Predictors of patient reported outcomes and cost of care in younger men with newly diagnosed prostate cancer. The Prostate 69: 1067-1076, 2009
  172. Canter D, Guzzo TJ, Resnick MJ, Bergey MR, Sonnad SS, Tomaszewski J, VanArsdalen K, Malkowicz SB. A thorough pelvic lymph node dissection in the presence of positive margins is associated with better clinical outcomes in radical cystectomy patients. Urology 74:161-165, 2009
  173. Bishay VL, Crino PB, Wein AJ, Malkowicz SB, Trerotola SO, Soulen MC, Stavropoulos SW. Embolization of giant renal angiomyolipomas: Technique and results. J Vasc Interv Radiol. 21:67-72, 2010
  174. Jayadevappa R, Chhatre S, Wein AJ, Schwartz S, Malkowicz SB. A measure of quality of care in prostate cancer patients. Med. Decis Making. 30:234-45, 2010
  175. Resnick MJ, Guzzo TJ, Canter DJ, Tomaszewski JE, Bergy MR, Sonnad S, Wein AJ, Malkowicz SB. Defining pathologic parameters to predict biochemical failure in patients with positive surgical margins at radical prostatectomy: Implications for adjuvant radiation therapy. 105:1377-80, 2010
  176. Jayadevappa R, , Chhatre S, Gallo J, Schwartz JS and Malkowicz SB. Association between utility and treatment among prostate cancer patients. Qual Life Res.19:711-20, 20110
  177. Jayadevappa R, Chharte S, Wein AJ, Schwartz S, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. [ The Prostate, in press ]
  178. Halbert CH, Coyne J, Weathers B, Mahler B, Delmoor E, Vaughn D, Malkowicz SB, Lee D, Troxel AB. Racial differences in quality of life following prostate cancer diagnosis. (Urology. Epub 3-2010)
  179. Change S, Gomes CM, Hypolite JA, Marx J, Alanzi J, Zderic SA, Malkowicz B, Wein AJ, Chacko S. Detrusor overactivity is associated with the down-regulateion of large conductance calium- and voltage –activated potassium channel protein. Am J Physiol Renal Physiol. 298:F1416-23, 2010
  180. Jayadevappa R, Malkowicz SB, Chhatre S, Gallo J, Schwartz JS. Racial and ethinic variation in health resource use and cost for prostate cancer. BJUInt. (Epub 2-2010)
  181. Nickerson ML, Kostiha B, Brandt W, Fredericks W, Xu KP, Yu FS, Bold B, Chodosh J, Goldberg M, Lu DW, Yamada M, Tervo TM, Grutzmacher,D, Croasdale C, Hoeltzenbein M, Sutphin J, Malkowicz SB, Wessjohann L, Kruth HS, Dean M and Weiss JS. Function of a novel mitochondrial memberane protein UBIAD1 appears to be altered by schnyder corneal dystrophy mutations. PLoS 5:10760e, 2010
  182. Smith MR, Morton RA, Barnette G, Sieber PR, Malkowicz SB, Rodrigues D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. (Epub 8-2010)
  183. Patel RP, Mucksavage P, Ramchndani P, Hanno PM, and Malkowicz SB. Idiopathic partial thrombosis of the corpus Cavernosum. Urology (Epub 4-2010)
  184. Mucksavage P, Mitchell C, Kutikov A, Wein AJ, Torigian D, Malkowicz SB. Anthropometeric Differences in obese men with biochemical failure after radical retropubic prostatectomy. Urol Oncol (in press, 2010)
  185. Jayadevappa R, Chhatre S, Johnson JC, Malkowicz SB. Association between ethnicity and prostate cancer outcomes across hospital and surgeon volume groups. Health Policy (Epub 8- 2010)
  186. Resnick MJ, Bergey M, Magerfleish L, Tomaszewski JE, Malkowicz SB, Guzzo TJ. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJIU (Epub 9-10)
  187. Guzzo……Malkowicz, MRI in T1c In press Urologic Oncology
  188. Guzzo…….Malkowicz Adjuvant chemo in LN+ cystectomy patients. In press Canadian J Urol
  189. Jayadevappa R……Malkowicz Indirect Costs In press The Prostate
  190. Muscavage P ……Malkowicz Size Correlation of Renal Tumors. In Press BJUI
  191. Huang W, Guzzo, Sanchez-Ortiz R, VanArsdalen K, Wein AJ, and Malkowicz SB. Ureteral margins have minimal outcome on cystectomy survival. Cancer [submitted]
  192. Abraham NE, Guzzo TJ, Tomaszewski JE, Chen Z, D’Amico A, VanArsdalen K, Wein, AJ, Malkowicz SB. Estimated tumor volume is a predictor of biochemical failure after radical prostatectomy in patients with organ confined Gleason 8-10 prostate cancer. J. Urol. Submitted.
Abstracts
  1. Malkowicz SB, Wein AJ, and Herlyn M: Selection of invasive transitional cell variants by adaptation to growth factor deprived, serum free media. J. Urology 143: 404A, 1990.
  2. Malkowicz SB, Rodeck U, Wein AJ, and Herlyn M.: Inhibition of human TCC metastases by an anti-epidermal growth factor receptor monoclonal antibody (MAb425) in an orthotopic nude mouse model. J. Urol. 145: 227A 1991.
  3. Malkowicz SB, Li WJ, Sorger T, Wein AJ, and Levin RM: The characterization of rabbit bladder smooth muscle in culture and its response to fibroblast growth factor. J. Urology 147: 311 A, 1992.
  4. Malkowicz SB, Broderick GA, Van Arsdalen K, Wein AJ and Whittington R: Treatment of localized prostate cancer with laparoscopic PLND and perineal 103 palladium seeds. Mid Atlantic Conference 1992.
  5. Overmoyer B, Fox K, Tomaszewski J, Malkowicz SB, MacDermott M, Kay A, Spiegelman M, Schuchter L: A phase II trial of R-verapamil and infusional vinblastine (Velban) in advanced renal cell carcinoma. University of Pennsylvania Cancer Center, ASCO Proceedings 12: 251, 1993.
  6. Carbone DJ, Wein AJ, and Malkowicz SB: Effectiveness of urine cytology in the diagnosis of transitional cell carcinoma. AUA Mid Atlantic Conference, 1993.
  7. Malkowicz SB, Wein AJ, and Alavi A: FDG-positron emission tomography in genitourinary tumors. AUA Mid-Atlantic Meeting, 1993.
  8. Cangiano TG, Malkowicz SB, Wein AJ and Tomaszewski JE: Patterns of seminal vesicle invasion in radical prostatectomy specimens and their association with clinical parameters.
    AUA 1994.
  9. Tessier CD, Ramchandani P, Carr J, Wein AJ, and Malkowicz SB: Use of MRI in diagnosing vena caval involvement in renal tumors. Mid Atlantic AUA, 1994.
  10. Malkowicz SB, Soucek M, Carr J, Tomaszewski J, Wein AJ, and Schnall M.: In vivo and in vitro MR imaging of the normal and pathologic bladder wall at 1.5T - 4.7T. Mid Atlantic AUA Meeting, 1994.
  11. Montone K, Malkowicz SB, Greene M, and Tomaszewski JE: In situ and immunohisto- chemical expression of Her2/neu oncogene in transitional cell carcinoma. J Urol 153: 456A, 1995.
  12. Malkowicz SB, Peterson N, Thomas J, McGarvey, and Greene MI: Inhibition of transitional cell carcinoma growth by a peptide mimetic of an anti-neu monoclonal antibody complementarity-determining region. AUA May 1996.
AUA Abstracts 2008
  1. Mucksavage P, Mitchell CR, Kutikov A, Wein AJ, Torigian DA, Malkowicz SB: Anthropomorphic differences in obese men with biochemical failure after radical retropubic prostatectomy. AUA 2008, vol 179 (4), A189, pg 67.
  2. Brucker BM, Bergey M, Resnick MJ, Sonnad S, Canter D, Guzzo TJ, Rebbeck TR, Wein AJ, Malkowicz SB: The impact of obesity on biochemical failure after radical prostatectomy in African-American and European American patients. AUA 2008, vol 179 (4), A428, pg 152.
  3. Jayaveddepa R, Chhatre S, Weiner M, Soldo B, Wein AJ, Malkowicz SB: Variations in care of older men with prostate cancer. AUA 2008, vol 179 (4), A460, pg 162.
  4. Kao GD, Dowling ML, Malkowicz SB: Modulation of CD44-Expressing bladder cancer cells by histone deacetylase inhibitors: Increasing the efficacy of chemo-radiation? AUA 2008, vol 179 (4), A755, pg 263.
  5. Fredericks WJ, Wang H, Zheng Y, Boyer J, Schullery D, Aqui N, Lal P, Tomaszewski J, McGarvey T, Malkowicz SB: Elevated TERE 1 protein induces cytokine expression in J82 bladder cancer and human immune cells. AUA 2008, vol 179 (4), A756, pp 263-264.
  6. Zheng Y, Malkowicz SB, Mohanan S, Chang S, Wein AJ, Chacko S: Generation of a human detrusor smooth muscle cell line. AUA 2008, vol 179 (4), A1572, pp 537-538.
  7. Canter D, Guzzo TJ, Resnick MJ, Sonnad S, Bergey M, Tomaszewski J, VanArsdalen K, Malkowicz SB: The finding of positive surgical margins on pathological examination of radical cystectomy specimens portends a poor prognosis. AUA 2008, vol 179 (4), A1610, pg 550.
  8. Canter D, Guzzo TJ, Resnick MJ, Sonnad S, Bergey M, Tomaszewski J, VanArsdalen K, Malkowicz SB: The presence of lymphovascular invasion in radical cystectomy specimens for patients with transitional cell carcinoma independently predicts poor clinical outcomes. AUA 2008, vol 179 (4), A1611, pg 550.
AUA Mid-Atlantic Abstracts Oct 2007
  1. Guzzo TJ, Bandara A, Magerfleish, Bergey M, Sonnard S. VanArsdalen KV, Vaughn DE, Malkowicz SB. The impact of lymph node density on the outcomes of adjuvant therapy in N+ cystectomy patients.
  2. Canter D, Guzzo TJ, Chung B, Vira M, Chen Z, Tomaszewski J, Sanchez R, Van Arsdalen K, Wein AJ, and Malkowicz SB. The impact of hydronephrosis on recurrence and disease specific survival in high grade bladder cancer.
  3. Resnick MJ, Guzzo TJ, Brucker BM, Bergy MR, Sonnad S, Wein AJ, Malkowicz SB. The impact of volume stratification in patients with a single core of positive cancer on prostate needle biopsy.
Non-Peer Reviewed Original Publications Editorials, Reviews, Chapters
  1. Malkowicz SB, and Perloff LJ: Urological consideration in renal transplantation. Surgery, Gynecology and Obstetrics, 160, 579-588, 1985.
  2. Malkowicz SB and Wein AJ: The pharmacologic treatment of voiding dysfunction.Urology Grand Rounds Series, Lesson 6, Marion Laboratories, 1985.
  3. Malkowicz SB, and Perloff LJ: Urologic aspects of renal transplantation pp. 501-520. A Clinical Manual of Urology, Hanno PM and Wein AJ, eds. Appleton-Century-Crofts, Norwalk CT., 1987.
  4. Malloy TR, and Malkowicz SB: Pharmacologic treatment of impotence. Urol. Clinics of N.A., 14: 297-305, 1987.
  5. Levin RM, Malkowicz SB, and Wein AJ: Basic research models and methods in neuromuscular studies of the lower urinary tract. pp. 122-143. Neurology and Urodynamics: Principles and Practice, Yalia SV, McGuire EJ, Elbadawi A, and Blaivas JG, eds. MacMillan Publishing Co., New York, NY, 1988.
  6. Malkowicz SB, and Wein AJ: Epidemiology and Natural History of Prostatic Carcinoma. pp.4-11. Cancer of the Prostate: Current practice/future directions, Wein, AJ and Malkowicz SB, eds. CoMed Communications, Philadelphia, PA 1989.
  7. Wein AJ, and Malkowicz SB: Cancer of the Prostate: Current practice/future directions, Series Editors. CoMed Communications, 1989.
  8. Wein AJ and Malkowicz SB: Controversies in the management of prostate cancer. Series Editors, CoMed Communications, 1990.
  9. Malkowicz SB, Kimmel B, Wein AJ and Herlyn M: The selection and phenotypic characterization of invasive variants of transitional cell carcinoma. Surgical Forum 42: 700-702, 1991.
  10. Wein AJ and Malkowicz SB: Controversies in the management of prostate cancer II. Series Editors, CoMed Communications, 1991-1992.
  11. Malkowicz SB and Wein AJ: Adult Genitourinary Cancer: A Clinical Manual of Urology, pp 419-480. Hanno PM and Wein AJ, eds., Appleton Century Crofts, Norwalk, CT., 2nd edition 1994.
  12. Malkowicz SB, Urinary Diversion: A Clinical Manual of Urology, pp 481-498. Hanno PM and Wein AJ, eds., McGraw-Hill, Inc., NY, 2nd edition 1994.
  13. Malkowicz SB: Interstitial Cell Tumors of the Testis: Current Urologic Therapy: Seidman EJ, Hanno PM, and Kaufman JJ eds. W.B. Saunders, Orlando, Florida, 3rd edition, pp. 504-505, 1994.
  14. Malkowicz SB: Leydig Cell Tumors of the Testis: Current Urologic Therapy, Seidman EJ, Hanno PM, and Kaufman JJ eds. W.B. Saunders Co., Orlando, Florida, 3rd edition, pp. 506-508, 1994.
  15. Malkowicz SB, Pressler L, Robbins S, Tomaszewski J, Wein AJ, and Linnenbach: Chromosome 9 LOH 9 analysis in transitional cell carcinoma. Surgical Forum 45: 805-808, 1994.
  16. Malkowicz SB: Diseases and disorders of kidneys and urinary tract: The Instant Exam Review for the USMLE Step 3. Appleton & Lange, Inc., Norwalk, CT, 17 321-342, 1994.
  17. Malkowicz SB: Current Opinions in Urology - Editorial Comment for bladder and testis cancer. Volume 5: 2, 1995.
  18. Malkowicz SB: Clinical aspects of renal tumors. Seminars in Rontgenography. Miller, W.J. Volume 30, 2: 102-115, 1995.
  19. Malkowicz, SB: Loss of chromosome 9 heterozygosity analyzed in transitional cell carcinoma. AUA Today, December 1995.
  20. Malkowicz SB and Vaughn DE: Chemotherapy for Muscle Invasive Bladder Cancer. Urology 47: 602-614, 1996.
  21. Malkowicz SB: Superficial bladder cancer: incremental insight. (Editorial) J Urol 155: 488-89, 1996.
  22. Malkowicz SB: Renal/Urinary System in USMLE Step I Review: The study guide, ed. Goldberg JS, Sage Publications, Inc. Thousand Oaks pp 439-452, 1996.
  23. Malkowicz SB: Serum PSA elevation in the post radical prostatectomy patient. The Urologic Clinics of North America 23: 665-675, 1996.
  24. Malkowicz SB: Molecular Biology, Editor, World Journal of Urology 14: 1, 1996.
  25. Whittington R and Malkowicz SB: Hormonal and radiation therapy profiles of decision. Vol 12 audiotape 1996.
  26. Malkowicz SB: Surgery, reconstructive surgery. Editorial comment. Current Opinion in Urology 7: U70-U72, 1997.
  27. Malkowicz SB, and Wein AJ: Approach to the patient with a prostate nodule or elevated PSA. Chapter 208: 1281-1284 Textbook of Internal Medicine, 3rd edition. Kelley W.N. ed. Lippincott-Raven Publishers, Philadelphia 1997.
  28. Malkowicz SB, and Wein AJ Prostate Cancer. Chapter 224: 1354-1357 Textbook of Internal Medicine, 3rd edition. Kelley W.N. ed. Lippincott-Raven Publishers, Philadelphia 1997.
  29. Malkowicz SB: Retroperitoneal tumors: diagnosis, staging, surgery, management and prognosis. Eds Oesterling JE and Richie JP. Chapter 36: 539-557, Urologic Oncology, W.B. Saunders 1997.
  30. Malkowicz SB: Diseases of the renal and urologic systems: The Instant Exam Review for the USMLE Step 3. Goldberg JS ed., 2nd edition, Appleton & Lange, Inc., Norwalk, CT. 1997.
  31. Malkowicz SB: Current Opinion in Urology. Editorial comment: Bladder and Testis Cancer 8: 1, U3-U4, 1998.
  32. Malkowicz SB: Editorial comment: Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma. The Journal of Urology 159: 1168-1173, 1998.
  33. Malkowicz SB: Editorial Comment: Calculating prostate cancer volume pre-operatively: the D’Amico equation and some other observations. The Journal of Urol 159: 1998-2003, 1998.
  34. Malkowicz SB: Diseases of the renal and urologic systems: The Instant Exam Review for the USMLE Step 2. Goldberg JS ed., 3rd edition, Appleton & Lange, Inc., Norwalk, CT. 1998.
  35. Malkowicz SB and Johnson JO: Gene Therapy for Prostate Cancer. Hematology & Oncology Clinics of North America, 12: 649-664, 1998.
  36. Gottschalk A, Smith DA, Malkowicz SB, Wein AJ. Letter to the Editor: Preemptive analgesia for prostatectomy. JAMA 280: 517-518, 1998.
  37. Malkowicz SB, Editorial comment: Hazard analysis for bladder cancer recurrence. J of Urol 161: 57-61, 1999.
  38. Malkowicz SB and Goldberg JS: Renal System and Urology. Appleton & Lange’s Outline Review for the USMLE Step 2. Appleton & Lange, Inc., Stamford, CT, 17 619-650, 1999.
  39. Malkowicz SB: The Application of human complement factor H-related protein (BTA trak) in monitoring patients with bladder cancer. Urologic Clin of NA 27:63-73, 2000.
  40. Malkowicz SB. Renal Cell Carcinoma- General. p. 452-453. The 5-minute Urology Consult. Ed. Gomella LG, Lippincott Williams Wilkins Philadelphia, PA 2000.
  41. Bernstein MR and Malkowicz SB. Renovascular Hypertension. p. 482-485. The 5-minute Urology Consult. Ed. Gomella LG, Lippincott Williams Wilkins Philadelphia, PA 2000.
  42. Sanchez-Ortiz RF, and Malkowicz SB. Embryonal Carcinoma. p. 520-521. The 5-minute Urology Consult. Ed. Gomella LG, Lippincott Williams Wilkins Philadelphia, PA 2000.
  43. Manganiotis A.N., Banner M.P., Malkowicz S.B. Urologic Complications of Crohn’s Disease. Surgical Clin of NA 81:197-215, 2001.
  44. Malkowicz SB. Disease of the Renal and Urologic Systems. Appleton & Lange’s Outline Review for the USMLE Step 3, Third Edition Chap. 17:376-396, 2001.
  45. Carroll PR, Fair WR, Grossfeld GD, Heston WDW, Lieberman R, Malkowicz SB, Stricker HJ, Sylvester J, Peehl DM, Meyer F, Hart C: Overview Consensus Statement. The First International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer Urol 58:1-4, 2001.
  46. Malkowicz SB: Urinary Diversion, in Clinical Manual of Urology. Eds Hanno, Wein and Malkowicz 18:561-576, 2001.
  47. Malkowicz SB, Sanchez-Ortiz R, Wein AJ: Urologic Oncology, in Clinical Manual of Urology. Eds Hanno, Wein, and Malkowicz 17:487-560, 2001.
  48. Vaughn DJ, Malkowicz SB, Chemotherapy in invasive bladder cancer. Oncology 15:763-775, 2001.
  49. Moul, JW, Kane CJ, and Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urologic Clinics of North America 28:459-472, 2001.
  50. Malkowicz SB: Assessing the Results of Cancer Treatment. Objectives for Urology Residency Education. 5th Edition. Soc University Urology p. 264-5, 2001.
  51. Sanchez-Ortiz RF, Wein AJ, and Malkowicz SB. Benign and Malignant tumors of the renal pelvis and ureter. . Objectives for Urology Residency Education. 5th Edition. Soc University Urology p. 269-271, 2001.
  52. Malkowicz SB: Management of Superficial Bladder Cancer. Chapter 77 Campbell’s Urology, 8th edition. Saunders, Philadelphia Walsh PC, Retick AB, Vaugn ED and Wein AJ eds. Pp.2785 -2802, 2002.
  53. Malkowicz SB: Prostate Cancer. Encyclopedia of Public Health 1st ed. ed. Breslow L, MacMillan Press. pp. 984-985, 2002.
  54. Malkowicz SB: Prostate Specific Antigen. Encyclopedia of Public Health 1st ed., ed Breslow L, MacMillan Press pp. 985-987, 2002.
  55. Levin BM, Vaughn DJ, and Malkowicz SB. Metastatic Prostate Cancer: Optimal Management Strategies. American Journal of Cancer 2:87-94, 2003.
  56. Malkowicz SB and Watson B. Basic research and urology: British Journal of Urology International (Editorial comment ) Brit. J. Urol. Int. 91: p. I , 2003.
  57. Malkowicz SB. The Surgical Anatomy of the Prostate, in Prostate Cancer- Science and Clinical Practice. Eds. Mydlo JH and Godec CJ Academic Press pp. 273-279, 2003.
  58. Goldberg JS and Malkowicz SB. Renal System and Urology. USMLE Step 2 Outline Review. Appleton and Lange, pp571-600, 2004.
  59. Malkowicz SB. Atlas of Genitourinary Oncology. Movas, Hudes, Olsson [book review] Gynecol. Oncology 92:390-1, 2004.
  60. Vaughn D, Lubinski E, and Malkowicz SB. The role of neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer. American Journal of Cancer 4:71-75, 2005.
  61. Malkowicz SB and Ferlise V: Retroperitoneal Tumors: Diagnosis, Staging, Surgery, Management and Prognosis. Pp 651-672. Richie JP and D’Amico AV. Urologic Oncology 2nd Edition, Elsevier Saunders, 2005.
  62. Malkowicz SB and Sanchez-Ortiz. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma[Editorial response] J.Urology October 2003.
  63. Vaughn DJ and Malkowicz SB. Neoadjuvant chemotherapy for bladder cancer. Urologic Clinics of NA 32:231-237, 2005.
  64. Malkowicz SB. Therapy for Superficial Bladder Cancer. Pp. 335-340. Textbook of Bladder Cancer., Eds. Lerner SP, Schoenberg MP, and Sternberg CN. Taylor and Francis Group, Abingdon, UK. 2006.
  65. Kutitov A, Guzzo T and Malkowicz SB. Benign and malignant prostate disorders. Radiologic Clinics of North America , 44:649-664, 2006.
  66. Malkowicz SB, Van Poppel, Mickisch G, Pansadoro V, Thuroff J, Soloway M, Chang S. Benson M, Fukuo I. Muscle-Invasive Urothelial Carcinoma of the Bladder pp.219-238, in Bladder Tumors, editors Soloway M, Carmack A, Khoury S. 1st International Consultation on Bladder Cancer, WHO, UICC, Health Publications Ltd, Paris France, 2006.
  67. Malkowicz SB, editorial comment JU March 2006.
  68. Malkowicz SB, editorial comment JU April 2006.
  69. Malkowicz SB Editorial Comment: Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. Shariat S. Ashfaq R, Sagalowsky AI, and Lotan Y. J. Urology 177:481-487, 2007.
  70. Guzzo T and Malkowicz SB Retroperitoneal Masses, in Clinical Manual of Urology 3rd Ed. Eds Hanno, Wein, and Malkowicz Saunders, 2007
  71. Malkowicz SB and Wein AJ Prostate and Bladder Cancer, in Clinical Manual of Urology. Eds Hanno, Wein, and Malkowicz Saunders 2007.
  72. Editorial: Malkowicz, SB. What should the urologist know about osteoporosis? J.Urology 182:2557-2558, 2009.
  73. Canter D and Malkowicz SB. Prostatic Abscess. Pp 292-293. In, 5 minute Urology Consult. Ed . Gomella L. Lippincot Williams and Wilkins, Philadelphia. 2010.
  74. Resnick M and Malkowicz SB. Urethra, Squamous Cell Carcinoma. Pp 494-495. In, 5 Minute Urology Consult. Ed . Gomella L. Lippincot Williams and Wilkins, Philadelphia. 2010.
  75. Brucker BM. and Malkowicz SB. Epididymitis. Pp 112-113. In, 5 Minute Urology Consult. Ed . Gomella L. Lippincot William and Wilkins, Philadelphia. 2010.
  76. Malkowicz, SB. Retroperitoneal Masses, Campbells
  77. Resnick M and Malkowicz SB, Renal Tumors. Steers and Chapple.
  78. White SE and Malkowicz SB. Management of the male urethra after cystectomy. Urol Clin North AM 37:475-479, 2010.
Books
  1. Co-Editor: Manual of Clinical Urology, 3rd Edition - Eds Hanno, Malkowicz and Wein McGraw Hill, Philadelphia, PA 2001.
  2. Associate-Editor: The 5-minute Urology Consult – Ed. Gomella LG., Assoc eds. Albala DM, Bagley DH, El-Gabry EA, Figueroa TE, Haas GP, Heaton JPW, Macchia RJ, Malkowicz SB, Manyak MJ, Milam DF, Moldwin RM, Moul JW, Petrou SP, Rivas DA, Robertson CN, Thrasher JB, Walther MM, Winfield HN, Wolf JS. Lippincott Williams & Wilkins, Phila., PA 2000.
  3. Co-Editor: Penn Manual of Clinical Urology, 4th Edition –Eds. Hanno PH, Malkowicz SB, and Wein AJ. Elsevier, Philadelphia PA 2007.

Dr. Bruce Malkowicz

 
footer Terms of Use Legal Disclaimer Site Map Contact Us Financial Assistance About Penn Medicine Privacy Statement
penn medicine